Roche and Fitterfly co-create 90-day diabetes programme
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Dupixent peak sales ambition raised to more than €13 billion
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Subscribe To Our Newsletter & Stay Updated